Intravitreal bevacizumab in XXXX : a prospective, observational case series.

@entity2297 @entity1 @entity1539 @entity158
OBJECTIVE: To examine the efficacy of intravitreal bevacizumab for @entity158 relief in eyes with @entity2297 . METHODS: In this prospective case series, 52 eyes with @entity2297 were administered intravitreal bevacizumab, 1.25 mg, and monitored for 6 months. The primary outcome measure was change in subjective @entity158 score. Intraocular pressure and @entity1539 were evaluated at each visit. Surgical intervention for control of intraocular pressure was performed according to clinical need. RESULTS: Forty-two @entity1 (44 eyes) completed the 6-month follow-up. Subjective @entity158 score was reduced significantly 1 week after intravitreal bevacizumab injection and lasted throughout the follow-up period (median [interquartile range]: baseline, 3 [0-6]; week 1, 1 [0-3]; month 1, 0 [0-1]; month 3, 0 [0-1]; and month 6, 0 [0-0]; Kruskal-Wallis   (2) 31.03; P  <  .001). A rapid, yet relatively transient, @entity1539 was also noted ( @entity1539 grade at baseline, 4.0 [3-4]; week 1, 2.5 [1-4]; month 1,  2.0 [1-4]; month 3, 3.0 [2-4]; and month 6, 3.0 [2-4],   (2) 23.33; P  <  .001). Four eyes (8%) required more than 1 injection to facilitate further intraocular surgery. CONCLUSIONS: Intravitreal bevacizumab is a useful adjunct in the management of @entity2297 , producing rapid relief of @entity158 . However, we found no evidence to suggest that intravitreal bevacizumab lowers intraocular pressure in eyes with angle closure; conventional medical, laser, and surgical treatment are still needed in these eyes.
